Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on August 05, 2025.

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults restatedResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1815.00

prior close

₹1770.30

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.3% vs market

Pharmaceuticals peers, median of 150sector-0.8%+0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.3

15m

+0.2

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-0.3-0.3-0.8+0.2

Next day

-4.7-1.5-3.2-2.2-2.5

-6.6-1.6-5.0-2.0-4.6

-5.8-2.9-2.9-2.6-3.2

-5.4-2.4-3.0-2.4-2.9

-7.4-2.4-5.0-2.0-5.5

-7.0-2.2-4.8-2.8-4.1

15d

-2.5-2.8+0.3-3.7+1.2

-4.5-0.7-3.7-2.9-1.5

-11.4+0.0-11.5-3.6-7.8

-12.4+0.2-12.6-5.6-6.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences' board, meeting on August 5, 2025, approved its unaudited Q1 FY26 standalone and consolidated financial results. Consolidated revenue from operations grew to ₹773.00 Cr from ₹719.72 Cr year-on-year (about 7% growth), while consolidated net profit jumped to ₹125.10 Cr from ₹89.55 Cr (about 40% growth). Standalone performance was even stronger, with revenue rising to ₹578.64 Cr from ₹456.69 Cr (~27% growth) and net profit surging to ₹99.99 Cr from ₹17.04 Cr. The auditor (Walker Chandiok & Co LLP) issued an unmodified limited review opinion with no qualifications. The company noted that prior period figures were restated following the final purchase price allocation for the Swiss Parenterals acquisition, and Q1 results include the recently acquired Eris Bionxt (formerly Chemman Labs), making them not strictly comparable to last year.

Likely market impact

Strong profit growth and margin expansion are positive signals for shareholders, though part of the standalone profit jump reflects subsidiary-level shifts and acquisition mix. The auditor change (from Deloitte Haskins & Sells to Walker Chandiok) and restated prior numbers may need monitoring, but overall the quarter shows healthy operating performance.